Pancreatic Cancer Research

ResearcherUniversity of OxfordActive in the last 2 years

Ganesh Radhakrishna

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6096-9695; OpenAlex author ID A5108726236, A5108989935. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
42
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 21

  1. The National Pancreatic Cancer Audit: Reducing Variation in Clinical Practice. Last author DOI 10.1016/j.clon.2026.104156↗
  2. Corrigendum to "SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer" [Radiother. Oncol. 155 … Co-author DOI 10.1016/j.radonc.2026.111610↗
  3. An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment. Co-author DOI 10.1093/bjr/tqae217↗
  4. Local radiotherapy polarized tumor-associated macrophages enhance the efficacy of Claudin18.2-targeted CAR-T therapy in pancreatic cancer. Co-author DOI 10.21037/jgo-2025-564↗
  5. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/ra… Co-author DOI 10.1016/j.ejca.2024.114236↗
  6. The role of stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) in locally advanced and borderline resectable pancreatic cancer. First author DOI 10.21037/atm-24-170↗
  7. The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study. Co-author DOI 10.1038/s41416-023-02220-2↗
  8. PACT-UK (PAncreatic Cancer reporting Template-UK): a cross-specialty multi-institutional consensus panel development of a standardised radiological reporting p… First author DOI 10.1136/bmjonc-2023-000055↗
  9. Normo- or Hypo-Fractionated Photon or Proton Radiotherapy in the Management of Locally Advanced Unresectable Pancreatic Cancer: A Systematic Review. Co-author DOI 10.3390/cancers15153771↗
  10. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2022.02.014↗
  11. Stereotactic Ablative Body Radiotherapy for Locally Advanced Unresectable Pancreatic Cancer: Current Views of the Public and Professionals. Last author DOI 10.1016/j.clon.2020.10.015↗
  12. SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. Co-author DOI 10.1016/j.radonc.2020.11.007↗
  13. Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". First author DOI 10.1038/s41416-020-01133-8↗
  14. Optimising treatment pathways for borderline and locally advanced pancreatic cancer: an adaptive personalised approach. Co-author DOI 10.1038/s41416-021-01416-8↗
  15. Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. First author DOI 10.1038/s41416-020-0980-x↗
  16. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for lo… Co-author DOI 10.1186/s12885-019-5307-z↗
  17. Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? Co-author DOI 10.1016/j.ejso.2018.07.047↗
  18. Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.08.001↗
  19. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. Co-author DOI 10.1186/s12885-016-2765-4↗
  20. Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Co-author DOI 10.1593/tlo.13724↗
  21. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Co-author DOI 10.1016/s1470-2045(13)70021-4↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan W. Valle · 7 shared papers, 2014–2025 · strength 1.01
  2. M. Hawkins · 8 shared papers, 2016–2026 · strength 0.97
  3. D. Holyoake · 7 shared papers, 2016–2026 · strength 0.89
  4. Somnath Mukherjee · 9 shared papers, 2013–2024 · strength 0.84
  5. Derek B. Grose · 6 shared papers, 2016–2026 · strength 0.74
  6. John A. G. Moir · 2 shared papers, 2023–2025 · strength 0.52
  7. Raneem Albazaz · 2 shared papers, 2023–2025 · strength 0.52
  8. Nigel Balfour Jamieson · 3 shared papers, 2020–2025 · strength 0.48
  9. Paula Ghaneh · 3 shared papers, 2020–2021 · strength 0.47
  10. Zhu Chuen Oong · 1 shared paper, 2024 · strength 0.46
  11. Pippa G. Corrie · 4 shared papers, 2019–2024 · strength 0.43
  12. Christopher Mark Jones · 3 shared papers, 2020–2024 · strength 0.35
  13. Katharine L. Aitken · 3 shared papers, 2020–2021 · strength 0.33
  14. Susanna Nallamilli · 1 shared paper, 2026 · strength 0.30
  15. Nigel John Trudgill · 1 shared paper, 2026 · strength 0.30
  16. Carmelo Corallo · 1 shared paper, 2025 · strength 0.28
  17. Tim Maughan · 3 shared papers, 2013–2024 · strength 0.27
  18. Chris N Hurt · 3 shared papers, 2013–2024 · strength 0.27
  19. Nicola de Liguori Carino · 2 shared papers, 2018–2022 · strength 0.26
  20. Mairead Geraldine McNamara · 2 shared papers, 2018–2022 · strength 0.26
  21. Songbing Qin · 1 shared paper, 2025 · strength 0.25
  22. Xiaokang Zhang · 1 shared paper, 2025 · strength 0.25
  23. Eric E. O’Neill · 2 shared papers, 2019–2024 · strength 0.24
  24. Esther G.C. Troost · 1 shared paper, 2023 · strength 0.20
  25. Sally Abdelfattah Elkhamisy · 1 shared paper, 2023 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.